Artiva Biotherapeutics reported total assets of $368.63M and total liabilities of $21.13M for the quarter ended Jun 2026, up 117.6% year over year. This balance sheet covers 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 3.53M | 5.33M | 5.92M | 6.53M | 7.16M | 7.81M | 8.46M | 9.11M | 9.78M | ||||
| Assets | |||||||||||||
| Current Assets | |||||||||||||
| Cash & EquivalentsCash & Equiv. | 53.70M | 65.89M | 53.50M | 48.20M | 34.25M | 55.88M | 40.23M | 30.40M | 28.47M | 123.00M | 26.70M | 86.80M | 349.40M |
| Receivables - NetNet Receivables | 1.03M | 0.57M | 0.57M | ||||||||||
| Receivables - OtherOther Receivables | 0.66M | 0.72M | 0.18M | 0.89M | 0.13M | 0.01M | 0.23M | 0.03M | 0.08M | -0.01M | -0.07M | 0.14M | |
| Receivables | 1.76M | 1.46M | 0.70M | 0.01M | 0.23M | 0.03M | 0.08M | -0.01M | -0.07M | 0.14M | |||
| Prepaid Assets | 1.09M | 1.73M | 3.23M | 3.06M | 3.81M | 6.67M | 6.48M | 4.59M | 1.96M | 2.74M | |||
| Current Assets | 79.82M | 49.75M | 150.56M | 188.63M | 170.00M | 149.07M | 129.52M | 112.67M | 88.74M | 352.28M | |||
| Non-Current Assets | |||||||||||||
| Property, Plant & Equipment (Net) | 8.10M | 7.32M | 6.86M | 6.37M | 7.06M | 6.89M | 6.98M | 6.62M | 6.22M | 5.67M | |||
| Long-Term Investments | 52.97M | ||||||||||||
| Other Non-Current Assets | 0.26M | 0.26M | 0.39M | 0.26M | 0.26M | 0.26M | 0.27M | 0.46M | 0.46M | 0.46M | 0.46M | 0.46M | 0.81M |
| Non-Current Assets | 25.29M | 26.16M | 75.03M | 20.95M | 21.26M | 20.32M | 19.34M | 18.27M | 17.21M | 16.36M | |||
| Assets | 105.11M | 75.91M | 225.60M | 209.58M | 191.26M | 169.39M | 148.86M | 130.94M | 105.95M | 368.63M | |||
| Liabilities | |||||||||||||
| Current Liabilities | |||||||||||||
| Accounts Payables | 0.61M | 0.82M | 1.22M | 1.12M | 2.04M | 1.22M | 0.85M | 0.35M | 2.29M | 1.39M | |||
| Payables | 0.61M | 0.82M | 1.22M | 1.12M | 2.04M | 1.22M | 0.85M | 0.35M | 2.29M | 1.39M | |||
| Accumulated Expenses | 8.02M | 6.21M | 8.34M | 7.39M | 6.38M | 5.84M | 7.03M | 9.60M | 5.56M | 9.90M | |||
| Other Accumulated Expenses | 2.86M | 2.22M | 1.47M | 1.00M | 1.00M | 0.90M | 1.02M | 1.13M | 2.77M | ||||
| Current Leases | 3.60M | 3.67M | 3.61M | 3.62M | 3.59M | 3.54M | 3.10M | 3.02M | 3.02M | 3.30M | |||
| Total Current Liabilities | 12.23M | 10.83M | 13.29M | 12.25M | 12.20M | 10.77M | 11.12M | 13.09M | 10.88M | 14.58M | |||
| Non-Current Liabilities | |||||||||||||
| Capital Leases | 0.11M | 0.07M | 0.04M | 0.01M | |||||||||
| Minority Interest | 119.65M | 119.65M | |||||||||||
| Operating Leases | 13.32M | 15.54M | 11.16M | 10.57M | 10.27M | 9.58M | 8.52M | 7.88M | 7.23M | 6.55M | |||
| Other Non-Current Liabilities | 25.10M | 27.72M | 0.07M | 0.07M | |||||||||
| Total Non-Current Liabilities | 25.62M | 22.88M | 24.53M | 22.87M | |||||||||
| Total Liabilities | 164.25M | 151.45M | 50.72M | 174.67M | 50.60M | 24.60M | 22.94M | 22.48M | 20.35M | 19.64M | 20.97M | 18.11M | 21.13M |
| Shareholder's Equity | |||||||||||||
| Common Equity | -164.25M | -151.45M | -162.01M | -174.67M | -191.10M | 201.00M | 186.64M | 168.78M | 149.04M | 129.22M | 109.97M | 87.85M | 347.50M |
| Liabilities and Shareholders Equity | 105.11M | 75.91M | 225.60M | 209.58M | 191.26M | 169.39M | 148.86M | 130.94M | 105.95M | 368.63M | |||
| Retained Earnings | -181.31M | -213.12M | -230.60M | -246.68M | -267.00M | -288.25M | -309.80M | -330.55M | -354.10M | -379.10M | |||
| Treasury Shares | 3.67M | 3.67M | 3.67M | 3.67M | 3.67M | 6.16M | 6.16M | 6.16M | 6.16M | 6.16M |